On January 18, 2024, EVP & GENERAL COUNSEL Paul Mahon sold 6,000 shares of United Therapeutics Corp (UTHR, Financial) as reported in a recent SEC Filing. United Therapeutics Corp is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Over the past year, the insider has sold a total of 140,500 shares and has not made any purchases. The latest transaction was part of a series of sales by the insider, contributing to the overall insider trend at United Therapeutics Corp.
The insider transaction history for United Therapeutics Corp shows a pattern of selling, with 0 insider buys and 64 insider sells over the past year.
On the day of the insider's recent sale, shares of United Therapeutics Corp were trading at $218.72, resulting in a market cap of $10.297 billion.
The stock's price-earnings ratio stands at 12.07, which is below both the industry median of 31.03 and the company’s historical median price-earnings ratio, suggesting a lower valuation relative to its peers.
According to the GuruFocus Value assessment, with a share price of $218.72 and a GF Value of $260.35, United Therapeutics Corp has a price-to-GF-Value ratio of 0.84, indicating that the stock is Modestly Undervalued.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
